semaglutide joe rogan Sanjay Gupta | There hasn't been a new medication approved to treat alcohol use disorder in the last 20 years. That may soon change with GLP-1 drugs like There hasn’t been a new

View Study PCO-02 Safety and Pharmacokinetics Trial (Phase 1)

Epidemiological studies and early clinical data suggest that GLP-1 receptor agonists may reduce the risk of neurodegenerative diseases including Alzheimer disease, Parkinson disease, and other forms of dementia

For example, some patients with Medicare discovered their expensive GLP-1 therapy (for CV risk reduction) was denied without explanations, leading to legal and public policy debate ( [21] ) ( [65] )

By integrating this knowledge into our practice, we can move beyond mere symptom management and work towards truly restoring health and enhancing the quality of life for these patients

Research suggests that regular movement may help preserve muscle, support balance and improve overall quality of life